Opinion

Video

Overcoming Barriers to NSCLC Biomarker Testing

Author(s):

Zofia Piotrowska, MD, MHS,Martin Dietrich, MD, PhD

Key opinion leaders delve into the challenges posed by payers, costs, out-of-pocket maximums, and the need for letters of medical necessity, while also addressing additional sources of resistance encountered in clinical practice.

Related Videos
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Sandip P. Patel, MD
Alec Watson, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Alison Schram, MD
January 16th 2025

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

NSCLC | © catalin | stock.adobe.com
January 14th 2025

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

FDA
January 13th 2025

Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC